CYC065

DRUG3 trials

Sponsors

Cyclacel Pharmaceuticals, Inc.

Conditions

AMLCancerMDSRelapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

CompletedNCT02552953

Cyclacel Pharmaceuticals, Inc.Cancer

Start: 2015-09-28End: 2023-08-25Updated: 2024-05-31

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

CompletedNCT03739554

Cyclacel Pharmaceuticals, Inc.Relapsed or Refractory Chronic Lymphocytic Leukemia

Start: 2019-01-25End: 2023-04-27Updated: 2024-01-25

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

CompletedNCT04017546

Cyclacel Pharmaceuticals, Inc.AML, MDS

Start: 2019-08-02End: 2023-04-05Updated: 2024-09-19

Related Papers

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

PLoS ONE2020-07-0981 citations

Evaluating CDK2/9 Inhibitor + Venetoclax in R/R AML or Myelodysplastic Syndrome

Oncology Times2020-03-12

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Blood2019-11-134 citations

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Blood2019-11-13

Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

Cancer Research2018-07-0112 citations

Abstract 3905: Strategic combination of the cyclin-dependent kinase inhibitor CYC065 with venetoclax to target anti-apoptotic proteins in chronic lymphocytic leukemia

Cancer Research2018-07-011 citations

Abstract 1309: CYC065, a novel CDK2/9 inhibitor, is an effective inducer of cell death and synergizes with BCL2 and BET inhibitors in B-cell lymphoma, including double-hit lymphomas

Cancer Research2016-07-151 citations